Boston Scientific Corporation $BSX Shares Purchased by Global Retirement Partners LLC

Global Retirement Partners LLC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 16.1% in the 3rd quarter, Holdings Channel reports. The fund owned 45,707 shares of the medical equipment provider’s stock after acquiring an additional 6,330 shares during the quarter. Global Retirement Partners LLC’s holdings in Boston Scientific were worth $4,462,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of BSX. Steph & Co. purchased a new stake in shares of Boston Scientific during the third quarter worth approximately $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at $25,000. FWL Investment Management LLC purchased a new position in Boston Scientific during the 2nd quarter worth $26,000. Sound Income Strategies LLC lifted its stake in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the period. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at about $30,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of BSX stock opened at $94.72 on Monday. The stock has a fifty day moving average price of $97.92 and a 200 day moving average price of $100.91. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The stock has a market cap of $140.42 billion, a PE ratio of 50.65, a P/E/G ratio of 1.68 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the business posted $0.63 earnings per share. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Truist Financial reduced their price objective on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, Canaccord Genuity Group decreased their target price on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $124.85.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 93,095 shares of company stock worth $9,305,450. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.